{"id":55494,"date":"2023-04-04T13:05:30","date_gmt":"2023-04-04T11:05:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/"},"modified":"2023-04-04T13:05:30","modified_gmt":"2023-04-04T11:05:30","slug":"bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/","title":{"rendered":"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics<\/a>, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present preclinical data supporting the ongoing clinical development of the lead investigational candidate BCA101, a bifunctional antibody designed to sequester the immunosuppressive TGF-\u03b2 in the tumor microenvironment (TME) of EGFR+ tumors, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida.<\/p>\n

<\/a><\/p>\n

\n\u201cThe preclinical data that will be presented at AACR supports the mechanism of action (MOA) of BCA101, which has demonstrated promising efficacy and a positive safety profile in an ongoing Phase 1\/1b clinical trial. Data from in vitro and in vivo studies provides further evidence of BCA101\u2019s potential, as a monotherapy and in combination with anti-PD-1, to induce durable anti-tumor responses in various tumor types, including head and neck cancer, our lead indication,\u201d said Rachel Salazar, SVP of R&D Strategy and Operations of Bicara Therapeutics. \u201cWe are also pleased to highlight our collaboration with researchers at the Belfer Center for Applied Cancer Science at Dana-Farber Cancer Institute to elucidate the effects of BCA101 on the tumor microenvironment of patients enrolled in the ongoing Ph1\/1b clinical trial and highlight the important role of TGF-\u03b2 neutralization in creating the conditions for an enhanced immune response.\u201d<\/p>\n

\nDetails of the presentations are as follows:<\/p>\n

\nTitle: <\/b>BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-\u03b2 signaling with potential for durable tumor growth inhibition
\n
Presenter: <\/b>Pradip Nair, Associate Research Director, Syngene International
\n
Presentation Type: <\/b>Poster
\n
Session Category: <\/b>Anticancer Immunotherapeutics
\n
Date\/Time: <\/b>Wednesday, April 19, 2023, 9:00 a.m. to 12:30 p.m. ET
\n
Location: <\/b>Section 22; Abstract #6339<\/p>\n

\nTitle: <\/b>Preliminary immune correlatives from BCA101 trial show favorable modulation of tumor immune microenvironment
\n
Presenter: <\/b>Patrick H. Lizotte, Lead Scientist, Dana-Farber Cancer Institute, Belfer Center for Applied Cancer Science
\n
Presentation Type: <\/b>Poster
\n
Session Category: <\/b>Immune Monitoring and Responses to Therapy
\n
Date\/Time: <\/b>Wednesday, April 19, 2023, 9:00 a.m. to 12:30 p.m. ET
\n
Location: <\/b>Section 39; Abstract #6677<\/p>\n

\nTitle: <\/b>An improved trispecific antibody (TsAb) platform for optimally engaging T cells for the treatment of solid tumor malignancies
\n
Presenter: <\/b>Avanish K. Varshney, Director of Antibody Discovery and Engineering, Bicara Therapeutics
\n
Presentation Type: <\/b>Poster
\n
Session Category: <\/b>Therapeutic Antibodies 1
\n
Date\/Time: <\/b>Monday, April 17, 2023, 9:00 a.m. to 12:30 p.m. ET
\n
Location: <\/b>Section 25; Abstract #1864<\/p>\n

\nAll presentations described here will be made available on the Bicara website following the conference.<\/p>\n

\nAbout Bicara Therapeutics
\n
<\/b>Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company\u2019s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara\u2019s lead asset, BCA101, a first-in-class EGFR \/ TGF-\u03b2-trap bifunctional antibody, is currently enrolling patients in a Phase 1\/1b study. Bicara\u2019s experienced team brings deep expertise across immunology, oncology, clinical development, business development and operational strategy. More information is available at www.bicara.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors<\/b>
Sarah McCabe
\n
Stern Investor Relations, Inc.
\n
sarah.mccabe@sternir.com<\/a>
212-362-1200<\/p>\n

Media<\/b>
Chris Railey
\n
Ten Bridge Communications
\n
chris@tenbridgecommunications.com<\/a>
617-834-0936<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present preclinical data supporting the ongoing clinical development of the lead investigational candidate BCA101, a bifunctional antibody designed to sequester the immunosuppressive TGF-\u03b2 in the tumor microenvironment (TME) of EGFR+ tumors, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55494","6":"format-standard","7":"category-industry"},"yoast_head":"\nBicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present preclinical data supporting the ongoing clinical development of the lead investigational candidate BCA101, a bifunctional antibody designed to sequester the immunosuppressive TGF-\u03b2 in the tumor microenvironment (TME) of EGFR+ tumors, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T11:05:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230404005173\/en\/1754426\/21\/Bicara-HorizLogo-2Color-500px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023\",\"datePublished\":\"2023-04-04T11:05:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/\"},\"wordCount\":540,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404005173\\\/en\\\/1754426\\\/21\\\/Bicara-HorizLogo-2Color-500px.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/\",\"name\":\"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404005173\\\/en\\\/1754426\\\/21\\\/Bicara-HorizLogo-2Color-500px.jpg\",\"datePublished\":\"2023-04-04T11:05:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404005173\\\/en\\\/1754426\\\/21\\\/Bicara-HorizLogo-2Color-500px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404005173\\\/en\\\/1754426\\\/21\\\/Bicara-HorizLogo-2Color-500px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/","og_locale":"en_US","og_type":"article","og_title":"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023 - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present preclinical data supporting the ongoing clinical development of the lead investigational candidate BCA101, a bifunctional antibody designed to sequester the immunosuppressive TGF-\u03b2 in the tumor microenvironment (TME) of EGFR+ tumors, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-04T11:05:30+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230404005173\/en\/1754426\/21\/Bicara-HorizLogo-2Color-500px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023","datePublished":"2023-04-04T11:05:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/"},"wordCount":540,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230404005173\/en\/1754426\/21\/Bicara-HorizLogo-2Color-500px.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/","url":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/","name":"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230404005173\/en\/1754426\/21\/Bicara-HorizLogo-2Color-500px.jpg","datePublished":"2023-04-04T11:05:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230404005173\/en\/1754426\/21\/Bicara-HorizLogo-2Color-500px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230404005173\/en\/1754426\/21\/Bicara-HorizLogo-2Color-500px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-to-present-preclinical-data-from-clinical-stage-bifunctional-antibody-program-bca101-at-aacr-annual-meeting-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55494"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55494\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}